X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs GLENMARK PHARMA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD GLENMARK PHARMA ORCHID PHARMA LTD/
GLENMARK PHARMA
 
P/E (TTM) x -0.6 13.6 - View Chart
P/BV x 0.5 3.8 12.0% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ORCHID PHARMA LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
GLENMARK PHARMA
Mar-16
ORCHID PHARMA LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1941,262 15.4%   
Low Rs35672 5.2%   
Sales per share (Unadj.) Rs276.5270.6 102.2%  
Earnings per share (Unadj.) Rs-79.224.9 -318.4%  
Cash flow per share (Unadj.) Rs-43.534.4 -126.3%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs53.9151.3 35.6%  
Shares outstanding (eoy) m70.45282.16 25.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.43.6 11.6%   
Avg P/E ratio x-1.438.9 -3.7%  
P/CF ratio (eoy) x-2.628.1 -9.4%  
Price / Book Value ratio x2.16.4 33.2%  
Dividend payout %08.0 0.0%   
Avg Mkt Cap Rs m8,067272,778 3.0%   
No. of employees `0002.810.0 27.9%   
Total wages/salary Rs m2,52713,782 18.3%   
Avg. sales/employee Rs Th6,956.17,614.9 91.3%   
Avg. wages/employee Rs Th902.51,374.8 65.6%   
Avg. net profit/employee Rs Th-1,993.0700.2 -284.6%   
INCOME DATA
Net Sales Rs m19,47776,340 25.5%  
Other income Rs m407356 114.3%   
Total revenues Rs m19,88476,696 25.9%   
Gross profit Rs m1,10314,172 7.8%  
Depreciation Rs m2,5192,691 93.6%   
Interest Rs m5,2271,789 292.2%   
Profit before tax Rs m-6,23610,048 -62.1%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1253,028 -4.1%   
Profit after tax Rs m-5,5807,019 -79.5%  
Gross profit margin %5.718.6 30.5%  
Effective tax rate %2.030.1 6.7%   
Net profit margin %-28.79.2 -311.6%  
BALANCE SHEET DATA
Current assets Rs m11,01459,096 18.6%   
Current liabilities Rs m32,06040,018 80.1%   
Net working cap to sales %-108.125.0 -432.4%  
Current ratio x0.31.5 23.3%  
Inventory Days Days9575 126.6%  
Debtors Days Days34119 28.2%  
Net fixed assets Rs m29,44039,075 75.3%   
Share capital Rs m705282 249.6%   
"Free" reserves Rs m2,04330,281 6.7%   
Net worth Rs m3,80042,703 8.9%   
Long term debt Rs m9,01824,873 36.3%   
Total assets Rs m46,510111,026 41.9%  
Interest coverage x-0.26.6 -2.9%   
Debt to equity ratio x2.40.6 407.4%  
Sales to assets ratio x0.40.7 60.9%   
Return on assets %-0.87.9 -9.6%  
Return on equity %-146.916.4 -893.4%  
Return on capital %-3.717.5 -21.3%  
Exports to sales %37.943.3 87.5%   
Imports to sales %22.67.4 304.5%   
Exports (fob) Rs m7,37833,044 22.3%   
Imports (cif) Rs m4,4065,672 77.7%   
Fx inflow Rs m7,51336,945 20.3%   
Fx outflow Rs m5,64961,066 9.3%   
Net fx Rs m1,865-24,122 -7.7%   
CASH FLOW
From Operations Rs m1,6823,449 48.8%  
From Investments Rs m-9,860-8,802 112.0%  
From Financial Activity Rs m6,6446,986 95.1%  
Net Cashflow Rs m-1,535934 -164.4%  

Share Holding

Indian Promoters % 32.3 48.3 66.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 6.9 66.7%  
FIIs % 3.3 34.4 9.6%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.5 526.7%  
Shareholders   84,811 56,727 149.5%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ALEMBIC LTD  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  WOCKHARDT LTD.  SUN PHARMA  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Aug 23, 2017 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS